Literature DB >> 27976752

Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.

M P Snee1, L McParland2, F Collinson2, C M Lowe2, A Striha2, D R Baldwin3, B Naidu4, D Sebag-Montefiore5, W M Gregory2, J Bestall6, J Hewison6, S Hinsley2, K N Franks1.   

Abstract

[This corrects the article DOI: 10.1186/s40814-016-0046-2.].

Entities:  

Year:  2016        PMID: 27976752      PMCID: PMC5154043          DOI: 10.1186/s40814-016-0095-6

Source DB:  PubMed          Journal:  Pilot Feasibility Stud        ISSN: 2055-5784


Erratum

After publication of the original article [1], it came to the authors’ attention that a source of funding had been inadvertently omitted from the Acknowledgements section; support from Yorkshire Cancer Research should have mentioned originally.
  1 in total

1.  The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection.

Authors:  M P Snee; L McParland; F Collinson; C M Lowe; A Striha; D R Baldwin; B Naidu; D Sebag-Montefiore; W M Gregory; J Bestall; J Hewison; S Hinsley; K Franks
Journal:  Pilot Feasibility Stud       Date:  2016-02-01
  1 in total
  1 in total

1.  Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment.

Authors:  Yanping Bei; Naoya Murakami; Yuko Nakayama; Kae Okuma; Tairo Kashihara; Vijay Parshuram Raturi; Hiroyuki Okamoto; Kana Takahashi; Koji Inaba; Hiroshi Igaki; Jun Itami
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.